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cated that the total direct and indirect cost increase was approx-
imately $106 per person per month.
PSK4
FREQUENCY AND COST CONSEQUENCES ASSOCIATED
WITH FAILURE OF MUPIROCIN AMONG UNCOMPLICATED
SKIN AND SKIN STRUCTURE INFECTIONS (USSSI)
Meissner BL1, Burch P S2, Cantrell CR2
1Xcenda, Palm Harbor, FL, USA, 2GlaxoSmithKline, Research Triangle
Park, NC, USA
OBJECTIVES: To derive the frequency and costs associated with
failure of initial mupirocin therapy among patients diagnosed
with uncomplicated skin and skin structure infections (uSSSI).
METHODS: A retrospective observational analysis was con-
ducted using data obtained from the Integrated Health care
Information Systems (IHCIS) dataset which contains nationally
representative managed care claims data. This analysis utilized
medical, pharmacy, and enrollment records between January 1,
2003 and April 30, 2006. Patients with a mupirocin prescription
and a corresponding ICD9 code for an uSSSI up to 15 days prior
to their index mupirocin prescription were eligible for the analy-
sis. A patient was classiﬁed as failing treatment with mupirocin
if they either: 1) received a second antibiotic commonly used to
treat uSSSI 5–30 days after their index mupirocin prescription
or 2) experienced an uSSSI-related hospitalization within 30 days
after the index mupirocin prescription. Among those patients
that were deﬁned as mupirocin failures the frequency and costs
(2005 US dollars) of a second uSSSI antibiotic, outpatient
encounter, and hospitalization was derived. RESULTS: A total
of 160,445 mupirocin prescriptions associated with an uSSSI
were dispensed during the study timeframe. Of those prescrip-
tions 12,650 (7.0%) resulted in failure. Among failures 93.8%
(11,867) required a second antibiotic contributing a mean cost
of $62 per prescription. Outpatient encounters were required 
by 40.3% (4782) of failures with a mean cost of $221 per
encounter. Only 9.0% of failures required a hospitalization, but
resulted in a mean cost of $6597 per hospitalization. This trans-
lates into an expected cost of $740.95 per mupirocin failure
among uSSSI patients. CONCLUSION: The management of
uSSSI is costly when initial pharmacologic therapy fails.
SKIN—Health Care Use & Policy Studies
PSK5
QUALITY OF DERMATOLOGIC CARE DELIVERED BY
PHYSICIAN ASSISTANTS:AN ANALYSIS OF
CLOTRIMAZOLE/BETAMETHASONE PROPIONATE
PRESCRIPTIONS
Satyaprakash A1, Jayawant SS2, Feldman SR1, Balkrishnan R2
1Wake Forest University School of Medicine, Winston Salem, NC,
USA, 2The Ohio State University College of Pharmacy, Columbus,
OH, USA
OBJECTIVES: The quality of dermatologic care provided by
physician assistants has not been well documented. This study
characterized the use of potentially inappropriate combination
medication clotrimazole/betamethasone diproprionate (a proxy
for potentially inappropriate care) by physician assistants 
compared to dermatologists and primary care physicians.
METHODS: Data obtained from the National Ambulatory
Medical Care Survey (1990–2000) were used to determine prac-
titioner factors associated with a prescription for clotrima-
zole/betamethasone diproprionate. For each visit sampled that
resulted in a dermatologic diagnosis, a patient log was completed
to include demographic data, reasons for patient visits, physician
diagnoses, services provided, and referral practices. For each
year, we assessed patient visits to include twenty highest derma-
tology-related primary ﬁeld diagnoses (using ICD-9 codes) at
which clotrimazole/betamethasone diproprionate was men-
tioned. Practitioners were grouped as dermatologists, dermatol-
ogy PAs, primary care providers, and primary care PAs, other
specialty physicians and other specialty PAs. One-way ANOVA
and multivariate logistic regression analyses using STATA 9.0
were tested the study objectives. RESULTS: PAs, regardless of
specialty, were more than four times as likely (OR: 4.3, 95%CI:
0.7, 25.6) to prescribe clotrimazole/betamethasone diproprion-
ate when they were the sole provider of care compared to when
under direct supervision by a physician (OR: 1.8, 95%CI: 0.4,
8.0). Dermatology PAs prescribed clotrimazole/betamethasone
diproprionate at a rate of 3.8%, compared to the PCP prescrip-
tion rate of 4.9% and the dermatologist prescription rate of
0.2%. The highest rate of clotrimazole/betamethasone dipropri-
onate prescription was seen in PAs practicing under PCPs,
16.9%. CONCLUSION: The quality of dermatologic care pro-
vided by dermatology physician assistants is closer to that of
primary care physicians than that of dermatologists, evidencing
a need for more extensive training for these practitioners.
However, the use of closely supervised PAs may help provide
more accessible and higher quality dermatologic care to all
patients than provided by primary care practitioners.
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OBJECTIVES: To determine the incremental direct health care
and indirect work loss costs experienced by employer-payers for
patients diagnosed with psoriasis (PS). METHODS: A de-
identiﬁed claims database consisting of 5.1 million covered lives
from 31 Fortune 500 self-insured employers over the period
1998–2005 was used. Each PS patient was matched with three
controls based on age and gender. The average monthly direct
health care costs (i.e., medical & pharmaceutical costs) were
computed for the respective groups. For the subset of patients
who were active employees, the indirect costs of lost work time
were calculated for each group, as measured by employer dis-
ability payments and sick leave time multiplied by the employee’s
wage. In addition, a multivariate two-part regression was used
to isolate the cost increase attributable to PS by controlling for
age, gender, year, comorbidities, and organ transplantation.
RESULTS: The univariate analysis showed that the PS patients
(N = 10,325) were associated with higher medical and pharmacy
costs than the control group (N = 30,975) by an average of $156
and $129 per person per month, respectively (medical: $439 vs.
$283, p < 0.0001; pharmacy: $209 vs. $81, p < 0.0001), bring-
ing the total increase in health care costs to $285 per person per
month ($648 vs. $364, p < 0.0001). In the subset of active
employees, the PS group (N = 2527) was associated with a higher
indirect work loss cost of $81 per person per month ($164 vs.
$83, p < 0.0001) than the control group (N = 6573). For each
cost category, a statistically signiﬁcant cost increase for PS
patients was conﬁrmed through the multivariate analysis
(adjusted incremental direct cost = $77, p = 0.024; adjusted
incremental indirect cost = $43, p = 0.022). CONCLUSIONS:
PS was associated with a statistically signiﬁcant increase in health
care and work loss costs. The multivariate analysis indicated that
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the total direct and indirect cost increase was approximately
$120 per person per month.
SMOKING—Cost Studies
PSM1
A LONG TERM COST–EFFECTIVENESS ANALYSIS MODEL FOR
SMOKING CESSATION IN MEXICO
Mould-Quevedo J, Saenz-Montanez J, Davila-Loaiza G
Pﬁzer Mexico, Mexico City, Mexico
OBJECTIVES: Smoking is associated with several acute and
chronic diseases in adult population that generate high medical
costs in the Mexican Health System. The purpose of the study
was to model the long term economic and health consequences
of two smoking cessation interventions (SCI) in Mexican
smokers attempting to quit from the health care payer’s per-
spective. METHODS: A cost–effectiveness assessment was devel-
oped using a Markov modeling approach adapted to the
Mexican smoker population. The model simulates costs and
effectiveness outcomes in a twenty-year period (1-year cycle) and
includes four potential comorbidities: chronic obstructive pul-
monary disease, lung cancer, coronary heart disease and stroke.
Comparators were: varenicline vs. nicotine patches, both in a
twelve-week treatment. Transition probabilities were obtained
according to Mexican epidemiologic data. Quit successful rates,
smoking relapses rates and relative risk of smoking associated to
the mentioned comorbidities were obtained from clinical trials
published in the literature. Effectiveness measure was the number
of life-years gained (LYG). Resource use and costs data was
obtained from representative published Mexican institutional
databases (only direct medical costs were included). Costs and
effectiveness measures were discounted 3% annually. Proba-
bilistic sensitivity analysis was performed and acceptability
curves were constructed. RESULTS: Varenicline, in a 20-year
period analysis, showed that could generate 132,304 more quit-
ters (4.9%); 4905 less subjects with comorbidities (1.5%); 3333
deaths avoided; and 22,598 LYG in comparison to the treatment
with nicotine patches. Also, varenicline was in the long term a
cost-saving strategy (expected cost reduction of US$10.6 mil-
lions—CI 95% US$9.8–US$11.7 millions). Results were robust
to Monte Carlo second order sensitivity analysis and accept-
ability curves showed the same results with a mean of 70% of
certainty. CONCLUSION: Despite its higher cost in the Mexican
market, varenicline was the SCI most cost–effective in the long
term for the management of patients attempting to quit.
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THE COST UTILITY OF VARENICLINE IN SMOKING
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Sollentuna, Sweden
OBJECTIVES: To calculate incremental cost-utility ratios for
varenicline as compared to bupropion in smoking cessation in
Sweden for a follow-up period of 20 and 50 years, respectively.
METHODS: The Beneﬁts of Smoking Cessation on Outcomes
(BENESCO) simulation model was employed in order to calcu-
late costs and beneﬁts accruing from smoking cessation. The
BENESCO model simulates morbidity and mortality over time
for a Swedish population of smokers. Four diseases were con-
sidered: chronic obstructive pulmonary disease, coronary heart
disease, stroke, and lung cancer. According to available epi-
demiological evidence, these diseases cover most of the health
problems associated with smoking. The advantage of smoking
cessation, simulated by the BENESCO model, is the decreased
incidence of the diseases considered. The beneﬁts of smoking ces-
sation were simulated for a male and female cohort, respectively.
In addition, the BENESCO model was extended in order to
include the indirect effects of smoking cessation on production
and consumption in the economy. All calculations were per-
formed in 2003 Swedish prices, assuming that 25% of the
smokers in each age-group make one attempt to quit smoking at
the outset of the simulation. RESULTS: Including indirect effects
on production, the incremental costs per QALY gained were
€2062 for men and €1196 for women over 20 years of follow-
up and €14,783 for men and €14,252 for women over 50 years
of follow-up, compared with bupropion. Including only direct
effects on health care costs, smoking cessation using varenicline
was cost-saving compared to bupropion treatment. Sensitivity
analysis indicated that the results are robust. Variation of treat-
ment efﬁciency and intervention cost, respectively, had a larger
effect on cost per QALY gained than other variables. CON-
CLUSION: Based on this model, the estimated costs per QALY
gained demonstrated that smoking cessation intervention using




ESTIMATING THE INCIDENCE AND PREVALENCE OF
SMOKING RELATED MORBIDITIES USING PROXY VALUES
Howard PA1, Knight CJ1, Baker CL2
1Heron Evidence Development Ltd, Letchworth, Hertfordshire, UK,
2Pﬁzer Inc, New York, NY, USA
OBJECTIVES: To estimate the incidence and prevalence of the
most burdensome smoking related morbidities in the US popu-
lation as part of the Beneﬁts of Smoking Cessation on Outcomes
(BENESCO) model. METHODS: We have developed a micro-
simulation Markov model to estimate the outcomes and costs of
a hypothetical cohort of US current smokers, a proportion of
whom (25%) will make a single attempt to quit smoking in the
ﬁrst year of a lifetime model. The BENESCO model estimates
the incidence and prevalence of smoking related diseases by using
the relative risks for mortality of the diseases as a proxy. The
hazard ratios from the Cancer Prevention Study II (Thun 2000)
were used as the basis for the required transformations. The inci-
dence and prevalence of the following smoking related diseases
were included in the model: lung cancer, chronic obstructive pul-
monary disease (COPD), coronary heart disease (CHD), stroke
and asthma exacerbations (attributed to smoking). Although the
model includes smokers aged 18 years and older, no excess events
were assumed to occur before the age of 35. RESULTS: Of 
the morbidities modelled, COPD was found as the most pre-
valent [peak estimates of individuals affected at model entry
point] disease among smokers [2.89 million], followed by CHD
[1.8 million], stroke [449,991], asthma exacerbations [395,829]
and lung cancer [68,348]. Incidence rates at model entry fol-
lowed a similar pattern to prevalence. The morbidities, which
were modelled, were more prevalent overall in female smokers
than their male counterparts. CONCLUSION: The estimates of
the incidence and prevalence of smoking related diseases in the
US population rely on methodology, which has been used else-
where in published, validated models (Orme 2001, Hoogen-
doorn 2003) and use underlying hazard ratios from a large,
independent US public health study. As such it could be expected
that the external validity of the estimates in the BENESCO model
is acceptable.
